{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,6,16]],"date-time":"2022-06-16T11:11:02Z","timestamp":1655377862636},"reference-count":8,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2008,11,20]],"date-time":"2008-11-20T00:00:00Z","timestamp":1227139200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2009,7]]},"DOI":"10.1007\/s00280-008-0870-z","type":"journal-article","created":{"date-parts":[[2008,11,19]],"date-time":"2008-11-19T15:20:08Z","timestamp":1227108008000},"page":"297-300","source":"Crossref","is-referenced-by-count":4,"title":["Biweekly docetaxel in recurrent ovarian cancer: a phase I dose finding study"],"prefix":"10.1007","volume":"64","author":[{"given":"Johanna","family":"M\u00e4enp\u00e4\u00e4","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arto","family":"Leminen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2008,11,20]]},"reference":[{"key":"870_CR1","doi-asserted-by":"crossref","first-page":"1682","DOI":"10.1093\/jnci\/djh323","volume":"96","author":"PA Vasey","year":"2004","unstructured":"Vasey PA, Jayson GC, Gordon A et al (2004) Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma. J Natl Cancer Inst 96:1682\u20131691","journal-title":"J Natl Cancer Inst"},{"key":"870_CR2","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.1016\/S0959-8049(97)00363-8","volume":"33","author":"SB Kaye","year":"1997","unstructured":"Kaye SB, Piccart M, Aapro M, Francis P, Kavanagh J (1997) Phase II trials of docetaxel (Taxotere) in advanced ovarian cancer\u2014an updated overview. Eur J Cancer 33:2167\u20132170","journal-title":"Eur J Cancer"},{"key":"870_CR3","doi-asserted-by":"crossref","first-page":"46","DOI":"10.3816\/CGC.2003.n.012","volume":"2","author":"V Karavasilis","year":"2003","unstructured":"Karavasilis V, Briasoulis E, Siarabi O, Pavlidis N (2003) Biweekly administration of low-dose docetaxel in hormone-resistant prostate cancer: pilot study of an effective subtoxic therapy. Clin Prostate Cancer 2:46\u201349","journal-title":"Clin Prostate Cancer"},{"key":"870_CR4","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1097\/01.cad.0000127333.06439.0e","volume":"15","author":"S V\u00e1zquez","year":"2004","unstructured":"V\u00e1zquez S, Grande C, Amenedo A et al (2004) Biweekly docetaxel as second-line chemotherapy of patients with advanced non-small cell lung cancer: a phase II study of the Galician Lung Cancer Group (GGCP 006\u201300). Anticancer Drugs 15:489\u2013494","journal-title":"Anticancer Drugs"},{"key":"870_CR5","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.eururo.2007.03.072","volume":"53","author":"A Bamias","year":"2008","unstructured":"Bamias A, Bozas G, Antoniou N et al (2008) Prognostic and predictive factors in patients with androgen-independent prostate cancer treated with docetaxel and estramustine: a single institution experience. Eur Urol 53:323\u2013331","journal-title":"Eur Urol"},{"key":"870_CR6","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/S0090-8258(03)00322-6","volume":"90","author":"T Oishi","year":"2003","unstructured":"Oishi T, Kigawa J, Fujiwara K et al (2003) A feasibility study on biweekly administration of docetaxel for patients with recurrent ovarian cancer. Gynecol Oncol 90:421\u2013424","journal-title":"Gynecol Oncol"},{"key":"870_CR7","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1200\/JCO.1996.14.5.1545","volume":"14","author":"GJ Rustin","year":"1996","unstructured":"Rustin GJ, Nelstorp AE, McLean P et al (1996) Defining response of ovarian cancer to initial chemotherapy according to S\u2013Ca 125. J Clin Oncol 14:1545\u20131551","journal-title":"J Clin Oncol"},{"key":"870_CR8","first-page":"383","volume":"23","author":"J Kaern","year":"2002","unstructured":"Kaern J, Baekelandt M, Trop\u00e9 CG (2002) A phase II study of weekly paclitaxel in platinum and paclitaxel-resistant ovarian cancer patients. Eur J Gynaecol Oncol 23:383\u2013389","journal-title":"Eur J Gynaecol Oncol"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-008-0870-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00280-008-0870-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-008-0870-z","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,28]],"date-time":"2019-05-28T10:06:55Z","timestamp":1559038015000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00280-008-0870-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,11,20]]},"references-count":8,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2009,7]]}},"alternative-id":["870"],"URL":"https:\/\/doi.org\/10.1007\/s00280-008-0870-z","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,11,20]]}}}